Lifecore Biomedical Stock Forecast

Stock Price Forecast

According to 5 analysts polled by S&P Global, Lifecore Biomedical stock has a consensus rating of "Buy" and an average price target of $6.67. The average 1-year stock price forecast is 21.49% higher than the current stock price, while the lowest is $5.00 (-8.93%) and the highest is $9.00 (+63.93%).

Price Target: $6.67 (+21.49%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$5.00	$6.67	$6.00	$9.00
Change	-8.93%	+21.49%	+9.29%	+63.93%

* Price targets were last updated on May 7, 2026.

Analyst Ratings

The average analyst rating for Lifecore Biomedical stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Nov '25	Dec '25	Jan '26	Mar '26	Apr '26	May '26
Strong Buy	2	2	2	2	2	2
Buy	0	0	0	1	1	1
Hold	3	3	3	2	2	2
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	5	5	5	5	5	5

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Michael Petusky Barrington	Barrington	Buy Maintains $6	Buy	Maintains	$6	+9.29%	May 7, 2026
Max Smock William Blair	William Blair	Buy Reiterates n/a	Buy	Reiterates	n/a	n/a	May 6, 2026
Matt Hewitt Craig-Hallum	Craig-Hallum	Buy Maintains $9	Buy	Maintains	$9	+63.93%	May 6, 2026
Steven Etoch Stephens	Stephens	Hold Reiterates $8.5 → $5	Hold	Reiterates	$8.5 → $5	-8.93%	Mar 17, 2026
Paul Knight KeyBanc	KeyBanc	Hold Maintains n/a	Hold	Maintains	n/a	n/a	Dec 29, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

122.17M

from 128.87M

-5.63%

from 128.87M

Revenue Next Year

130.23M

from 122.17M

6.60%

from 122.17M

EPS This Year

-0.81

from -0.43

EPS Next Year

-0.81

from -0.81

Fiscal Year	FY 2022	FY 2023	FY 2024	FY 2025	FY 2025	FY 2026
Period Ending	May 29, 2022	May 28, 2023	May 26, 2024	May 25, 2025	Dec 31, 2025	Dec 31, 2026
Revenue	111.27M	103.27M	128.26M	128.87M	129.46M	122.17M
Revenue Growth	10.31%	-7.19%	24.20%	0.47%	0.46%	-5.63%
Gross Profit	39.07M	27.99M	41.85M	40.30M	40.61M	39.31M
Gross Margin	35.11%	27.10%	32.63%	31.27%	31.37%	32.18%
Operating Income	-3.43M	-19.72M	-5.49M	-12.01M	-1.26M	2.12M
Net Income	-116.72M	-99.56M	12.01M	-38.72M	-30.79M	-39.36M
EPS	-	-	-	-	-0.43	-0.81
Free Cash Flow	-26.82M	16.29M	-20.27M	-29.04M	-	8.20M
No. Analysts	-	-	-	-	-	5

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	123.3M
Avg	122.2M
Low	120.0M

Revenue Growth

Revenue Growth	2026	2027	2028
High	-4.8%
Avg	-5.6%
Low	-7.3%

EPS Forecast

EPS	2026	2027	2028
High	-0.81
Avg	-0.81
Low	-0.81

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-